AbbVie inks $10.9B Apogee buyout to bag eczema prospect
AbbVie’s $10.9B bid for Apogee Therapeutics signals a high-stakes bet on next-gen autoimmune treatments—including a potential Dupixent rival.
📍 Where it landed
The story quieted without further updates on the deal’s progression or regulatory approvals. AbbVie’s acquisition of Apogee Therapeutics for $10.9 billion was announced but did not receive follow-up coverage. No details emerged on integration plans, clinical timelines, or potential impacts on existing treatments.
Epilogue added 44d ago, after coverage quieted.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Watch for updates on FDA review timelines for Apogee’s lead drug, as its approval trajectory could accelerate or delay AbbVie’s commercialization plans. Competition in the eczema space may intensify, with other players like Eli Lilly and Pfizer potentially accelerating their own pipeline candidates.
The deal’s impact on AbbVie’s stock and investor sentiment will also be closely monitored in the coming weeks.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 44d ago.
The reporting (6)
- AbbVie seals $10.9B deal to acquire Waltham biotech Apogee Therapeutics The Business Journals · 47d ago
- AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs BioPharma Dive · 47d ago
- AbbVie said to be reeling in Apogee and its Dupixent rival for almost $11B: report FirstWord Pharma · 47d ago
- AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion WSJ · 47d ago
- AbbVie strikes $10.9 billion deal for Apogee Therapeutics Yahoo Finance · 47d ago
- AbbVie inks $10.9B Apogee buyout to bag eczema prospect Fierce Biotech · 47d ago
The obvious questions
What is Apogee Therapeutics known for?
Apogee Therapeutics is a biotech firm focused on developing long-acting therapies for autoimmune and inflammatory diseases, including a lead candidate for eczema.
How does this deal compare to AbbVie’s past acquisitions?
Coverage does not yet specify direct comparisons, but the $10.9 billion price tag ranks among AbbVie’s largest deals, reflecting its strategic emphasis on immunology.
Will this acquisition affect AbbVie’s existing drugs like Humira?
The deal is framed as a long-term growth play to offset revenue pressures from patent expirations on drugs like Humira, though operational details remain pending.
Topics
Related trends
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
Sanofi’s new CEO Garijo outlines an R&D restructuring and expansion plan as the company balances strong second-quarter earnings against investor concerns.
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into pharmaceutical companies regarding clinical trial sites located in China.
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
Ipsen’s $1.75B bid for Kartos Therapeutics reshapes blood cancer drug development—with a twist on the deal’s structure
Lilly, J&J and AbbVie Hit New Highs
Healthcare stocks surge to record highs as investors pivot away from tech
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
European regulators have recommended revoking marketing authorization for the Amgen drug Tavneos due to concerns regarding the reliability of study data.
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Merck KGaA, Darmstadt, Germany, has entered into an $11.3 billion agreement to acquire Minneapolis-based life sciences firm Bio-Techne.